Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEHAW NASDAQ:ATNFW NASDAQ:LBPSW NASDAQ:XOMAO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEHAWAesther Healthcare Acquisition$0.01$0.01$0.06▼$0.33N/AN/A34,287 shsN/AATNFW180 Life Sciences$0.01+22.0%$0.01$0.00▼$0.04N/AN/A138,580 shs476,891 shsLBPSW4D pharma$0.00$0.04▼$1.29N/AN/A20,931 shsN/AXOMAOXOMA$25.38-0.5%$25.40$23.32▼$25.87N/AN/A2,938 shs1,418 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEHAWAesther Healthcare Acquisition0.00%0.00%+38.03%+92.16%-75.50%ATNFW180 Life Sciences0.00%+0.83%+50.62%+50.62%+15.09%LBPSW4D pharma0.00%0.00%0.00%0.00%0.00%XOMAOXOMA0.00%+0.51%-0.56%+1.52%+0.51%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AATNFW180 Life SciencesN/AN/AN/AN/AN/AN/AN/AN/ALBPSW4D pharmaN/AN/AN/AN/AN/AN/AN/AN/AXOMAOXOMAN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEHAWAesther Healthcare Acquisition 0.00N/AN/AN/AATNFW180 Life Sciences 0.00N/AN/AN/ALBPSW4D pharma 0.00N/AN/AN/AXOMAOXOMA 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/AN/AATNFW180 Life SciencesN/AN/AN/AN/AN/AN/ALBPSW4D pharma$522KN/AN/AN/AN/AN/AXOMAOXOMA$13.05MN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEHAWAesther Healthcare AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/AATNFW180 Life SciencesN/AN/A0.00∞N/AN/AN/AN/AN/ALBPSW4D pharmaN/AN/A0.00N/AN/AN/AN/AN/AN/AXOMAOXOMAN/AN/A0.00∞N/AN/AN/AN/A8/11/2025 (Estimated)Compare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/AATNFW180 Life SciencesN/AN/AN/AN/AN/ALBPSW4D pharmaN/AN/AN/AN/AN/AXOMAOXOMA$2.098.23%N/AN/AN/ALatest XOMAO, ATNFW, LBPSW, and AEHAW DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/21/2025XOMAOXOMAQuarterly$0.52348.28%7/3/20257/3/20257/15/2025(Data available from 1/1/2013 forward)Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEHAWAesther Healthcare AcquisitionN/AATNFW180 Life SciencesN/ALBPSW4D pharmaN/AXOMAOXOMAN/AInsider OwnershipCompanyInsider OwnershipAEHAWAesther Healthcare AcquisitionN/AATNFW180 Life SciencesN/ALBPSW4D pharmaN/AXOMAOXOMAN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEHAWAesther Healthcare Acquisition2N/AN/ANot OptionableATNFW180 Life Sciences7N/AN/ANot OptionableLBPSW4D pharmaN/AN/AN/ANot OptionableXOMAOXOMA10N/AN/ANot OptionableXOMAO, ATNFW, LBPSW, and AEHAW HeadlinesRecent News About These CompaniesPharmalittle: We’re reading about Bill Gates’ women’s health pledge, a Vertex pain drug failure, and moreAugust 5, 2025 | statnews.comSPromise of gamma delta bispecific antibodies prompts XOMA acquisitionAugust 5, 2025 | thepharmaletter.comTXoma Royalty to Acquire Lava TherapeuticsAugust 4, 2025 | marketwatch.comHillevax Shares Gain on Acquisition Deal with XOMA RoyaltyAugust 4, 2025 | msn.comXoma Royalty to Acquire Lava Therapeutics, End Development of Lead CandidateAugust 4, 2025 | precisionmedicineonline.comPXoma strikes deals to buy struggling biotechs HilleVax, LavaAugust 4, 2025 | finance.yahoo.comXoma Royalty to Acquire HilleVaxAugust 4, 2025 | marketwatch.comXOMA Royalty to acquire cancer drug developer LAVA TherapeuticsAugust 4, 2025 | msn.comXoma Royalty to Acquire Lava Therapeutics -- UpdateAugust 4, 2025 | marketwatch.comXOMA Royalty (XOMA) Moves 9.0% Higher: Will This Strength Last? - NasdaqJune 26, 2025 | nasdaq.comWhy XOMA Royalty Corporation’s (XOMA) Stock Is Down 5.18%May 1, 2025 | aaii.comAXOMA Royalty Stock Dividends | NASDAQ:XOMAO | BenzingaApril 22, 2025 | benzinga.comXoma completes sale of Kinnate Pipeline assets for up to $270MApril 15, 2025 | markets.businessinsider.comBig moves by small biotechs signal potential shift for investorsApril 15, 2025 | bizjournals.comXOMA Royalty Corporation's (NASDAQ:XOMA) Path To ProfitabilityApril 15, 2025 | finance.yahoo.comThe Analyst Verdict: XOMA Royalty In The Eyes Of 4 ExpertsMarch 28, 2025 | benzinga.comXOMA Royalty Corporation: XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business AchievementsMarch 18, 2025 | finanznachrichten.deXoma reports Q4 net loss $4M vs net loss $20.1M last yearMarch 17, 2025 | markets.businessinsider.comXOMA Royalty Corporation's (NASDAQ:XOMA) largest shareholders are retail investors with 38% ownership, institutions own 36%March 2, 2025 | finance.yahoo.comXoma price target lowered to $104 from $123 at H.C. WainwrightFebruary 3, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeXOMAO, ATNFW, LBPSW, and AEHAW Company DescriptionsAesther Healthcare Acquisition NASDAQ:AEHAW$0.0098 0.00 (0.00%) As of 08/8/2025Aesther Healthcare Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in New York, New York.180 Life Sciences NASDAQ:ATNFW$0.01 +0.00 (+22.00%) As of 08/8/2025 03:08 PM Eastern180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.4D pharma NASDAQ:LBPSW4D pharma plc, together with its subsidiaries, engages in the research, development, and production of live biotherapeutic products. The company develops therapeutic candidates, such as MRx0518; MRx-4DP000 for the treatment of asthma and COVID-19; MRx0029 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, including MRx1299 for solid tumors, MRx0005 for neurodegeneration, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. The company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda and MRx0518 in patients with solid tumors. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.XOMA NASDAQ:XOMAO$25.38 -0.12 (-0.47%) Closing price 08/8/2025 03:20 PM EasternExtended Trading$25.38 0.00 (0.00%) As of 08/8/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/04 - 08/08 Rocket Lab Reports Q2 Results: Is the Bull Thesis Still Intact? Airbnb Beats Earnings, But the Growth Story Is Losing Altitude Dutch Bros Just Flipped the Script With a Massive Earnings Beat Amazon Takes an Equity Stake in IonQ—Any Upside Potential? D-Wave Delivers Growth Shock—Investors Eye Quantum Future Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? Constellation Energy’s Earnings Beat Signals a New Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access Sale